B
Bionyra Pharma
Biotech & Life Sciences · Paris, France · Founded 2025
Next-generation biologics for immune-mediated inflammatory diseases MoreLess
Bionyra Pharma is a Paris-based, clinical-stage biopharmaceutical company developing next-generation biologics for severe immunological and inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis. Co-founded by Sofinnova Partners and Frederic Marrache, a former Sanofi global project head for clinical development in immunology and inflammation, the company is building its pipeline through an in-licensing strategy, having brought in three assets from partners including TrueLab Biopharmaceutical and NovaRock Biotherapeutics. Its most advanced programme, BYN-002, is a monoclonal antibody targeting TL1A, a signalling protein implicated in gastrointestinal inflammation.
Company overview
Bionyra Pharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2025
- Headquarters
- Paris, France
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 56.1
Valuation & funding
Bionyra Pharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2026 | $165M | $660M | Vives Partners · Apollo Health Ventures · Jeito Capital · Arkin Capital | ↗ |
Growth signals
Bionyra Pharma website traffic
Latest recorded traffic for Bionyra Pharma is 1.5K monthly website visits.
Comparisons
Bionyra Pharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Bionyra Pharma's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Bionyra Pharma has talent and traffic
In the news
Latest news about Bionyra Pharma
Recent press, funding announcements, and product moves mentioning Bionyra Pharma — open to read from the original sources.
Market sentiment
What the market is saying about Bionyra Pharma
An AI-synthesized read of the highest-engagement posts about Bionyra Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bionyra Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.